IFNG and cancer: Collectively, our CRISPR-Cas9 screens identified key nodes of resistance and sensitivity to IFN-γ in colorectal cell lines for further study, with considerable overlap with clinical reports of ICB resistance in patients5,6,7 and genetic screens interrogating cancer immune evasion in vitro10,28,29,32 and in vivo29,30,31 (Table S1).